Clinical Benefits of Achieving Deep Remission to Second-Line Therapy in Patients with Relapse/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) - a Real-World Study

被引：0
|
作者：
Wierda, William G.
Gauthier, Genevieve
Meissner, Brian
Guerin, Annie
Samp, Jennifer C.
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2130
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Real-World Outcomes of Second-Line Chronic Lymphocytic Leukemia Treatments: Retrospective Analysis of the Brazilian Registry of CLL
    de Lacerda, Marcelo Pitombeira
    Marques, Fernanda de Morais
    Pfister, Verena
    Parra, Flavia de Carvalho
    de Molla, Vinicius Campos
    Buccheri, Valeria
    Gaiolla, Rafael Dezen
    Fogliatto, Laura Maria
    Santucci, Rodrigo
    Bellesso, Marcelo
    Fortier, Sergio Costa
    Silveira, Talita M. B.
    Ribeiro, Glaciano
    Hamerschlak, Nelson
    Yamamoto, Mihoko
    Goncalves, Matheus Vescovi
    Chiattone, Carlos S.
    Arrais-Rodrigues, Celso
    BLOOD, 2022, 140 : 7041 - 7042
  • [2] COST-EFFECTIVENESS ANALYSIS OF ACALABRUTINIB FOR PATIENTS WITH RELAPSE AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL)
    Liu, Y.
    Han, S.
    VALUE IN HEALTH, 2024, 27 (12) : S87 - S87
  • [3] Real-world outcomes upon second-line treatment in patients with chronic lymphocytic leukaemia
    Vainer, Noomi
    Aarup, Kathrine
    Andersen, Michael Asger
    Wind-Hansen, Lise
    Nielsen, Tine
    Frederiksen, Henrik
    Enggaard, Lisbeth
    Poulsen, Christian Bjorn
    Niemann, Carsten U.
    Rotbain, Emelie C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 (05) : 874 - 886
  • [4] Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Jain, Nitin
    Keating, Michael J.
    Thompson, Philip A.
    Burger, Jan A.
    Ferrajoli, Alessandra
    Estrov, Zeev E.
    Borthakur, Gautam M.
    Takahashi, Koichi
    Bose, Prithviraj
    Fowler, Nathan H.
    Kadia, Tapan M.
    Daver, Naval G.
    Konopleva, Marina Y.
    Alvarado, Yesid
    Yilmaz, Musa
    DiNardo, Courtney D.
    Ohanian, Maro
    Pemmaraju, Naveen
    Jabbour, Elias
    Sasaki, Koji
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Garg, Naveen
    Wang, Xuemei
    Sondermann, Katrina
    Cruz, Nichole
    Wei, Chongjuan
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop M.
    Gandhi, Varsha
    Wierda, William G.
    BLOOD, 2019, 134
  • [5] BTK Inhibitors Versus Venetoclax as First- or Second-Line Therapy in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Evidence Study
    Roeker, Lindsey E.
    Han, Yi
    Teschemaker, Anna
    Mato, Anthony R.
    Thompson, Meghan C.
    AMERICAN JOURNAL OF HEMATOLOGY, 2025, 100 (04) : 720 - 723
  • [6] Real-World Outcomes Among 2L+Patients with Chronic Lymphocytic Leukemia (CLL) By Line of Therapy (LOT)
    Davids, Matthew S.
    Ambrose, Jacob
    De Nigris, Enrico
    Prescott, Jennifer
    Leng, Siyang
    Farooqui, Mohammed Z. H.
    Gandra, Shravanthi R.
    Zettler, Christina M.
    Fernandes, Laura L.
    Wang, Ching-Kun
    Shadman, Mazyar
    BLOOD, 2023, 142
  • [7] Real-world treatment patterns in first line and relapsed Chronic Lymphocytic Leukemia (CLL)
    Feinberg, Bruce
    Schenkel, Brad
    McBride, Ali
    Ellis, Lorie
    Radtchenko, Janna
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S204 - S205
  • [8] Characterization and predictors of sleep disturbance in patients with relapsed/refractory chronic lymphocytic leukemia (r/r CLL)
    Westbrook, Travis D.
    Maddocks, Kami J.
    Andersen, Barbara L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] Acquired Mutations in Patients (Pts) with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) That Progressed in the ALPINE Study
    Brown, Jennifer R.
    Li, Jessica
    Eichhorst, Barbara F.
    Lamanna, Nicole
    O'Brien, Susan M.
    Tam, Constantine S.
    Qiu, Luqui
    Ramakrishnan, Vanitha
    Huang, Ruiqi
    Shi, Yang
    Idoine, Adam
    Salmi, Tommi
    Cohen, Aileen Cleary
    Shadman, Mazyar
    BLOOD, 2023, 142
  • [10] Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Rogers, Kerry A.
    Thompson, Philip A.
    Allan, John N.
    Coleman, Morton
    Sharman, Jeff P.
    Cheson, Bruce D.
    Izumi, Raquel
    Frigault, Melanie M.
    Quah, Cheng
    Raman, Rakesh K.
    Wang, Min Hui
    Kipps, Thomas J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S282 - S283
12345